Helix Net Income from 2010 to 2026

HBP Stock  CAD 1.83  0.03  1.67%   
Helix BioPharma Net Loss yearly trend continues to be very stable with very little volatility. Net Loss is likely to drop to about -6.3 M. During the period from 2010 to 2026, Helix BioPharma Net Loss quarterly data regression pattern had range of 15.9 M and standard deviation of  3,196,014. View All Fundamentals
 
Net Loss  
First Reported
2010-07-31
Previous Quarter
-950 K
Current Value
-1 M
Quarterly Volatility
1.5 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Helix BioPharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Helix BioPharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 8.6 K, Interest Expense of 8.6 K or Selling General Administrative of 2.7 M, as well as many indicators such as Price To Sales Ratio of 20.62, Dividend Yield of 0.0 or PTB Ratio of 4.62. Helix financial statements analysis is a perfect complement when working with Helix BioPharma Valuation or Volatility modules.
  
This module can also supplement various Helix BioPharma Technical models . Check out the analysis of Helix BioPharma Correlation against competitors.
Evaluating Helix BioPharma's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Helix BioPharma Corp's fundamental strength.

Latest Helix BioPharma's Net Income Growth Pattern

Below is the plot of the Net Income of Helix BioPharma Corp over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Helix BioPharma Corp financial statement analysis. It represents the amount of money remaining after all of Helix BioPharma Corp operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Helix BioPharma's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Helix BioPharma's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported (5.21 M)10 Years Trend
Slightly volatile
   Net Income   
       Timeline  

Helix Net Income Regression Statistics

Arithmetic Mean(8,005,576)
Coefficient Of Variation(39.92)
Mean Deviation2,061,458
Median(7,911,000)
Standard Deviation3,196,014
Sample Variance10.2T
Range15.9M
R-Value0.35
Mean Square Error9.5T
R-Squared0.12
Significance0.16
Slope223,658
Total Sum of Squares163.4T

Helix Net Income History

2026-6.3 M
2025-6 M
2024-5.2 M
2023-9.3 M
2022-6.3 M
2021-6.1 M
2020-7.9 M

About Helix BioPharma Financial Statements

Helix BioPharma investors utilize fundamental indicators, such as Net Income, to predict how Helix Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Net Loss-6 M-6.3 M
Net Loss-10.7 M-11.2 M
Net Loss-6 M-6.3 M
Net Loss(0.08)(0.09)
Net Income Per E B T 0.90  0.76 

Pair Trading with Helix BioPharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Helix BioPharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Helix BioPharma will appreciate offsetting losses from the drop in the long position's value.

Moving against Helix Stock

  0.72HD Home Depot CDRPairCorr
  0.39CRE Critical ElementsPairCorr
  0.33BCE-PT Bce Inc PrefPairCorr
  0.32DNG Dynacor Gold MinesPairCorr
The ability to find closely correlated positions to Helix BioPharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Helix BioPharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Helix BioPharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Helix BioPharma Corp to buy it.
The correlation of Helix BioPharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Helix BioPharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Helix BioPharma Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Helix BioPharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Other Information on Investing in Helix Stock

Helix BioPharma financial ratios help investors to determine whether Helix Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Helix with respect to the benefits of owning Helix BioPharma security.